+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Not all DTC patients with N positive disease deserve the attribution "high risk". Contribution of the MSDS trial

Not all DTC patients with N positive disease deserve the attribution "high risk". Contribution of the MSDS trial

Journal of Surgical Oncology 112(1): 9-14

To investigate if patients with thyroid carcinoma having N1a disease are at the same risk with N1b using the collective of the well-defined European prospective Multicentre Study Differentiated Thyroid Cancer (MSDS). Overall (OS) and event free survival (EFS) were calculated. Cox multivariable regression analysis was performed in order to calculate Hazard ratios (HR). EFS was significantly decreased only in patients with N1b metastasis as compared to N0 patients and became worse when N1a was concomitantly affected. A superior survival in favor of N1a patients as compared to N1b patients with regard to EFS was also observed. The patients having N1a disease showed no differences in the EFS as compared to N0. OS did not differ significantly in any of the groups. There was an increased HR for events with regards to histology, T-stage, tumor size, UICC stage and cervical lymph node metastasis. Tumor size showed a significantly increased risk for OS. Patients with pT3b and pT4a tumors with N1b are of higher risk for relapse, albeit not affecting overall survival. Patients with N1a are of no higher risk. The risk stratification of these patients may be adapted accordingly.

(PDF emailed within 0-6 h: $19.90)

Accession: 058427582

Download citation: RISBibTeXText

PMID: 26074402

DOI: 10.1002/jso.23948

Related references

Risk stratification of patients with locally aggressive differentiated thyroid cancer. Results of the MSDS trial. Nuklearmedizin. Nuclear Medicine 49(3): 79-84, 2010

Screening asymptomatic patients with diabetes for unknown coronary artery disease: does it reduce risk? An open-label randomized trial comparing a strategy based on exercise testing aimed at revascularization with management based on pharmacological/behavioural treatment of traditional risk factors. DADDY-D Trial (Does coronary Atherosclerosis Deserve to be Diagnosed and treated early in Diabetics?). Trials 10(): 119-119, 2010

The msds pocket dictionary what does an msds mean terms used on msds first edition. Accrocco, J O (Ed ) The Msds Pocket Dictionary: What Does An Msds Mean Terms Used on Msdss, First Edition 61p Genium Publishing Corp : Schenectady, New York, Usa Illus Paper 61p, 1987

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiology, Biomarkers & Prevention 23(10): 1997-2008, 2015

Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease. British Journal of Ophthalmology 83(10): 1186-1189, 1999

Routine FDG PET-CT in patients with a high-risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases. Journal of the European Academy of Dermatology and Venereology 26(11): 1431-1435, 2013

Attribution style and psychosis: evidence for an externalizing bias in patients but not in individuals at high risk. Psychological Medicine 36(6): 771-778, 2006

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 121(23): 2575-2583, 2010

Deletion 11q23 identifies B-CLL patients at high risk for molecular disease persistence after high dose therapy Results from the CLL3 trial of the DCLLSG. Onkologie 23(Sonderheft 7): 76, October, 2000

Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer 109(5): 907-914, 2007

Implantable cardioverter defibrillator therapy for patients with chronic Chagas' disease: a randomized trial may not be necessary in high-risk patients. Europace 11(4): 537-537, 2009

Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. Bmj 348(): G3318-G3318, 2014

Does coronary Atherosclerosis Deserve to be Diagnosed earlY in Diabetic patients? The DADDY-D trial. Screening diabetic patients for unknown coronary disease. European Journal of Internal Medicine 26(6): 407-413, 2016

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. Journal of Clinical Oncology 31(28): 3531-3539, 2013